CLINICAL_TRIALS
trial_result
· 2022-08-04
Clinical Trial Update: Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma [Phase 2]
Summary
Phase 2 trial evaluating intralesional rituximab for conjunctival indolent lymphoma shows completion of the study.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Andres J. M. Ferreri | Conditions: Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Status: COMPLETED